

**DOCTOR**  
ORSHER, STUART  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) MO  
P: [REDACTED]

**PATIENT**  
EPSTEIN, JEFFREY  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**SAMPLE**  
Specimen ID: 104364919  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

Notes: NON FASTING

**CLINICAL REPORT**

**Clinical Abnormalities Summary:** (May not contain all abnormal results; narrative results may not have abnormal flags. Please review entire report.)

Glucose	105 HI	LD	235 HI		
Cholesterol	226 HI	Triglycerides	1510 HI		
IgG BAND 41	Positive *				
Hemoglobin A1C	5.7 HI	HERPES I Ab.(IgG)	7.40 HI	HERPES II Ab.(IgG)	5.70 HI
CK	346 HI	CHLAMYDIA AB. IgG/IgM (30)	SEE BELOW *	ANA SCREEN	Positive *
ANA TITER (IFA)	1:160 HI	PNEUMO Ab TYPE 1 (58)		PNEUMO Ab TYPE 4 0.6 LO (58)	
PNEUMO Ab TYPE 8 (58)	0.4 LO	PNEUMO Ab TYPE 9 (9N) (58)	0.4 LO	PNEUMO Ab TYPE 11 (58)	
PNEUMO Ab TYPE 19 (19F) (58)	0.8 LO	PNEUMO Ab TYPE 23 (23F) (58)		PNEUMO Ab TYPE 26 0.5 LO (58)	
PNEUMO Ab TYPE 56 (18C) (58)	1.3 LO	PNEUMO Ab TYPE 68 (9V) (58)	0.4 LO	B.Henselae IgG At1:64 * (3)	

**\* CHEMISTRY \***

Total Protein	7.3	5.9-8.4	g/dL
Albumin	4.5	3.5-5.2	g/dL
Globulin	2.8	1.7-3.7	g/dL
A/G Ratio	1.6	1.1-2.9	
Glucose	105 HI	70-99	mg/dL
Sodium	140	135-147	mmol/L
Potassium	4.3	3.5-5.5	mmol/L
Chloride	101	96-108	mmol/L
CO2	22	22-29	mmol/L
BUN	20	8-23	mg/dL
Creatinine	0.92	0.80-1.30	mg/dL
e-GFR	88	>or=60	mL/min
e-GFR, African American	102	>or=60	mL/min
BUN/Creat Ratio	21.7	10.0-28.0	
Calcium	9.7	8.6-10.4	mg/dL
Uric Acid	7.4	3.4-8.5	mg/dL
Iron	82	59-158	ug/dL
Bilirubin, Total	0.5	<1.2	mg/dL
LD	235 HI	135-225	U/L
Alk Phos	67	40-156	U/L

**ORSHER, STUART**  
D  
O  
C  
T  
O  
R  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
R Acct #: (C3070) NO  
P: [REDACTED]

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**S  
A  
M  
P  
L  
E**  
Specimen ID: 104364919  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

AST	7	<40	U/L
PHOSPHORUS	3.2	2.7-4.5	mg/dL
ALT	<5	<41	U/L

NOTE: The result for ALT has been confirmed by repeat analysis.

GGTP	23	10-71	U/L
------	----	-------	-----

**-\* CARDIOVASCULAR/LIPIDS \*--**

Cholesterol	226 HI	<200	mg/dL
Triglycerides	1510 HI	<150	mg/dL

NOTE: The result for Triglycerides has been confirmed by repeat analysis.

HDL CHOL., DIRECT	TNP	>40	mg/dL
-------------------	-----	-----	-------

Test Not Performed: Unable to perform HDL test due to elevated Triglycerides (>1200).

HDL as % of Cholesterol	TNP	>14	%
Chol/HDL Ratio	TNP	<7.4	
LDL/HDL Ratio	TNP	<3.56	
LDL Cholesterol	Can't Calc	<100	mg/dL

NOTE: Unable to calculate LDL due to a Triglyceride level of greater than 400 mg/dL.

VLDL, CALCULATED	Can't Calc	7-32	mg/dL
------------------	------------	------	-------

Can't Calc: One or more components was outside the measurable range. We are unable to calculate.

Test Not Performed: One or more components were not available to perform calculation.

**-----\* HEMATOLOGY \*-----**

WBC	6.10	3.66-11.99	x10(3)/uL
RBC	5.15	4.20-5.90	x10(6)/uL
HGB	15.4	12.3-17.0	gm/dL
HCT	44.0	39.3-52.5	%
MCV	85.4	80.0-100.0	fL
MCH	29.9	25.0-34.1	pg
MCHC	35.0	29.0-35.0	gm/dL
RDW	14.9	10.9-16.9	%
POLYS	46.9	36.0-78.0	%
LYMPHS	39.0	12.0-48.0	%
MONOS	7.7	0.0-13.0	%

**DOCTOR**  
ORSHER, STUART  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) MO  
P: [REDACTED]

**PATIENT**  
EPSTEIN, JEFFREY  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**SAMPLE**  
Specimen ID: 104364919  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

EOS	5.4	0.0-8.0	%
BASOS	0.8	0.0-2.0	%
IMMATURE GRANULOCYTES	0.2	0.0-1.6	%
Platelet Count	248	144-400	x10(3)/uL
MPV	9.6	8.2-11.9	fL

**-----\* URINALYSIS \***

Color	YELLOW	YELLOW, STRAW, AMBER	
Character	CLEAR	CLEAR	
Specific Gravity Ur	1.019	1.003-1.030	
pH Urine	6.5	5.0-8.0	
Protein, Urine	NEGATIVE	NEGATIVE	
Glucose, Urine	NEGATIVE	NEGATIVE	
Ketone, Urine	NEGATIVE	NEGATIVE	
Urobilinogen Urine	0.2	0.2-1.0	mg/dL
Bilirubin, Urine	NEGATIVE	NEGATIVE	
Blood, Urine	NEGATIVE	NEGATIVE	
Nitrites Urine	NEGATIVE	NEGATIVE	
Leukocyte Esterase	NEGATIVE	NEGATIVE	
Crystals Urine	NONE	NONE	
Crystal Amt. Urine	NONE	NONE	PER HPF
WBC, Urine	0-4	0-4	PER HPF
RBC, Urine	NONE SEEN	NONE SEEN	PER HPF
Epithelial Cells, Ur	NONE	NONE-FEW	
Cast, Hyaline, Urine	0-4	0-4	PER LPF
Cast, Granular, Ur	NONE SEEN	0-1	PER LPF
Cast, RBC, Urine	NONE SEEN	0-1	PER LPF
Bacteria, Urine	NONE	NONE-FEW	

**-----\* MICROBIOLOGY \***

CULTURE, URINE	NO GROWTH	NO GROWTH	
SITE: URINE			

**-\* LYME WB, IgG W/BANDS \*---**

IgG BAND 18	Negative	Negative	kDa
IgG BAND 23	Negative	Negative	kDa
IgG BAND 28	Negative	Negative	kDa
IgG BAND 30	Negative	Negative	kDa
IgG BAND 39	Negative	Negative	kDa
IgG BAND 41	Positive *	Negative	kDa
IgG BAND 45	Negative	Negative	kDa
IgG BAND 58	Negative	Negative	kDa

**ORSHER, STUART**  
D  
O  
C  
T  
O  
R  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) **NO**  
P: [REDACTED]

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**S  
A  
M  
P  
L  
E**  
Specimen ID: 104364919  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

IgG BAND 66	Negative	Negative	kDa
IgG BAND 93	Negative	Negative	kDa

NOTE: LYME ANTIBODY (IgG) by WESTERN BLOT is considered to be positive if any 5 out of the following 10 bands are present: 18, 23, 28, 30, 39, 41, 45, 58, 66, 93 kDa.

Lyme IgG INTERPRETATION WB	Negative	Negative	
<b>* LYME WB, IgM W/BANDS *---</b>			
IgM BAND 23	Negative	Negative	kDa
IgM BAND 39	Negative	Negative	kDa
IgM BAND 41	Indetermin	Negative	kDa

NOTE: LYME ANTIBODY (IgM) by WESTERN BLOT is considered to be positive if any 2 out of the following 3 bands are present: 23, 39, 41 kDa.

Lyme IgM INTERPRETATION WB	Negative	Negative	
----------------------------	----------	----------	--

<b>-----* ALLERGENS IgE *-----</b>			
IgE, SERUM	TNP	<or=114.0	kU/L

Test Not Performed: Specimen is LIPEMIC.  
ALLERGEN INTERPRETATION:

CONCENTRATION (kUA/L)	INTERPRETATION
<0.10	Absent
0.10 - 0.34	Very Low
0.35 - 0.69	LOW
0.70 - 3.49	Moderate
3.50 - 17.49	High
17.50 - >100.00	Very High

<b>-----* MISCELLANEOUS *-----</b>			
Hemoglobin A1c	5.7 HI	<5.7	%

HEMOGLOBIN A1c AND eAG REFERENCE RANGES

A1c(%)	DIABETES CATEGORY*
<5.7	Normal (non-diabetic)
5.7-6.4	Increased risk of diabetes
=>6.5	Consistent with diabetes

  

A1c(%)	eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)
6	126
7	154
8	183
9	212
10	240
11	269
12	298

**DOCTOR**  
ORSHER, STUART  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) MO  
P: [REDACTED]

**PATIENT**  
EPSTEIN, JEFFREY  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**SAMPLE**  
Specimen ID: 104364919  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

\*recommended ranges-American Diabetes Association(2010)

NOTE: The amount of glycated hemoglobin as measured by the HbA1c test may be overestimated in African Americans and should not be used as the sole parameter of glycemic burden. Similarly, hemolysis, genetic hemoglobin variants and chemically modified hemoglobin derivatives (as seen in renal failure, smoking, aspirin use) may also affect glycated hemoglobin levels.

ABO/Rh BLOOD TYPE	A Pos		
TSH	TNP	0.178-4.530	uIU/mL

Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.

THYROXINE (T4)	TNP	4.9-12.9	ug/dL
T3 UPTAKE (T3U)	TNP	24.3-39.0	%
THYROXINE, FREE (FT4)	TNP	0.80-1.73	ng/dL
FREE T4 INDEX	TNP	1.5-3.8	
T3 (THYRONINE), TOTAL	TNP	72-180	ng/dL
ALBUMIN (SPEP)	TNP	3.29-5.55	g/dL
ALPHA-1-GLOB. (SPEP)	TNP	0.17-0.41	g/dL
ALPHA-2-GLOB. (SPEP)	TNP	0.42-0.99	g/dL
BETA GLOB. (SPEP)	TNP	0.47-1.22	g/dL
GAMMA GLOB. (SPEP)	TNP	0.65-1.67	g/dL
M SPIKE	TNP	Not Detected	g/dL
SPEP GRAPH	TNP	See Graph	

NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please RESUBMIT a fasting specimen at your earliest convenience.

FERRITIN	TNP	22-322	ng/mL
----------	-----	--------	-------

Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.

HEP. A Ab., TOTAL	TNP	Non-Reactive	
HEP. B CORE Ab. IGG	TNP	Non-Reactive	
HEP. B SURF. AB.	TNP	Non-Reactive	
HEP. B SURF. AG	TNP	Non-Reactive	
HEP. BE AB.	TNP	Negative	
HEP. BE AG.	TNP	Non-Reactive	
IgA, SERUM	225	70-400	mg/dL
IgG, SERUM	1047	700-1600	mg/dL
IgM, SERUM	46	40-230	mg/dL
RPR	Non-Reactive	Non-Reactive	Titer

**ORSHER, STUART**  
D  
O  
C  
T  
O  
R  
P:  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) MO  
P: [REDACTED]

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
P:  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**Specimen ID: 104364919**  
S  
A  
M  
P  
L  
E  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

**HERPES I Ab.(IgG) 7.40 HI <0.90 AI**

INTERPRETATION OF RESULTS FOR HSV-1 AND HSV-2 IgG ANTIBODY

Antibody Index	Result	Interpretation
<0.90 AI	Negative	No HSV-IgG antibody detected
0.90-1.09 AI	Equivocal	Equivocal result. Repeat in 4-6 weeks
>or=1.10 AI	Positive	IgG antibody detected

\*\*\*Comment: This assay is type specific and will differentiate between Herpes Simplex 1 and 2 infections. Test results should be interpreted in conjunction with clinical history. The performance of this assay has not been established for pediatric populations, for neonatal screening or for testing the immunocompromised.

**HERPES II Ab.(IgG) 5.70 HI <0.90 AI**

INTERPRETATION OF RESULTS FOR HSV-1 AND HSV-2 IgG ANTIBODY

Antibody Index	Result	Interpretation
<0.90 AI	Negative	No HSV-IgG antibody detected
0.90-1.09 AI	Equivocal	Equivocal result. Repeat in 4-6 weeks
>or=1.10 AI	Positive	IgG antibody detected

\*\*\*Comment: This assay is type specific and will differentiate between Herpes Simplex 1 and 2 infections. Test results should be interpreted in conjunction with clinical history. The performance of this assay has not been established for pediatric populations, for neonatal screening or for testing the immunocompromised.

**TESTOSTERONE, TOT.,S. TNP 193.0-740.0 ng/dL**

NOTE: Patients receiving the drug Nandrolone cannot be tested for TESTOSTERONE, total using the EIA method (test code 0379-8) due to a strong interference from the drug. Clinicians are asked to request Testosterone, Total by LC/MS/MS (test code J451-6) for these patients.

CK	346 HI	39-308	U/L
H.PYLORI Ab.,IgG	0.34	See Below	
H.PYLORI Ab.,IgA	0.49	See Below	
H.PYLORI Ab.,IgM	0.29	See Below	
LYME DISEASE Ab.	0.44	<0.91	
Babesia microti IgM IFA (58)	<1:20	<1:20	
Babesia microti IgG (58)	<1:64	<1:64	

Sera from patients shown to have been infected by other tick-borne pathogens, Babesia duncani, Rickettsia rickettsii and Borrelia burgdorferi, were screened and found negative by the B. microti IgG IFA. \*This test was developed and its performance characteristics determined by Viracor Eurofins. It has not been cleared or approved by the U.S. Food and Drug Administration.  
Testing Performed At:  
Viracor Eurofins

**ORSHER, STUART**  
D  
O  
C  
T  
O  
R  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) MO  
P: [REDACTED]

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**Specimen ID: 104364919**  
S  
A  
M  
P  
L  
E  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

1001 NW Technology Drive  
Lee's Summit, MO 64086  
(800) 305-5198  
CLIA# 26D-0983643

Tetanus Antibody IgG (58) 1.37 >0.1 IU/mL

\*This test was developed and its performance characteristics determined by Viracor Eurofins. It has not been cleared or approved by the U.S. Food and Drug Administration.

Testing Performed At:  
Viracor Eurofins  
1001 NW Technology Drive  
Lee's Summit, MO 64086  
[REDACTED]  
CLIA# 26D-0983643

Diphtheria Antibody IgG (58) 0.31 >0.1 IU/mL

Testing Performed At:  
Viracor Eurofins  
1001 NW Technology Drive  
Lee's Summit, MO 64086  
[REDACTED]  
CLIA# 26D-0983643

HIV Ag/Ab TNP Non-Reactive

Test Not Performed: Unable to perform HIV testing, specimen is LIPEMIC.

Assay Information: Assay for the detection of HIV p24 antigen and antibodies to Human Immunodeficiency Virus Type 1, including Group O (HIV-1 + "O") and/or Type 2 (HIV-2)  
Method: Chemiluminescence (Siemens Healthcare Diagnostics)

**CHLAMYDIA AB. IgG/IgM (30) SEE BELOW \***

C. pneumoniae IgM Titer	<1:20		<1:20
C. trach IgM Titer	<1:20		<1:20
C. psittaci IgM Titer	<1:20		<1:20
C. pneumoniae IgG Titer	1:128	H	<1:64
C. trach IgG Titer	<1:64		<1:64
C. psittaci IgG Titer	<1:64		<1:64

--INTERPRETIVE INFORMATION: C. psittaci IgG Titer  
--The Chlamydia antibody test contains both species- and genus-specific antigens, and serological cross-reactions may be seen in

**ORSHER, STUART**  
D  
O  
C  
T  
O  
R  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
R Acct #: (C3070) MO  
P: [REDACTED]

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**S  
A  
M  
P  
L  
E**  
Specimen ID: 104364919  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

--both acute and convalescent samples (less than 1:128). A C.  
--pneumoniae-specific reaction will exhibit titers twofold or  
--greater than titers observed with the C. trachomatis or C.  
--psittaci serology. Any IgG titer may indicate past exposure to  
--that particular species. IgG titers in recently infected  
--individuals are typically greater than or equal 1:512.  
--The Chlamydia microimmunofluorescent assay slides utilize C.  
--psittaci, C. pneumoniae, and nine serotypes of C. trachomatis. The  
--LGV strains of C. trachomatis are not included in this assay.  
--Test developed and characteristics determined by ARUP  
--Laboratories. See Compliance Statement A: aruplab.com/CS  
--www.aruplab.com, Julio Delgado, MD - Lab. Director

B QUINTANA AB G/M (30) SEE BELOW

B. quintana Ab, IgM < 1:16  
--  
--

--INTERPRETIVE INFORMATION: Bartonella quintana Ab, IgM  
-- Less than 1:16 ..... Negative-No significant level of  
-- Bartonella quintana IgM antibody  
-- detected.  
-- 1:16 or greater ..... Positive-Presence of IgM antibody  
-- to Bartonella quintana detected,  
-- suggestive of current or recent  
-- infection.  
--The presence of IgM antibodies suggests recent infection. Low  
--levels of IgM antibodies may occasionally persist for more than 12  
--months post-infection.  
--Test developed and characteristics determined by ARUP  
--Laboratories. See Compliance Statement A: aruplab.com/CS  
--www.aruplab.com, Julio Delgado, MD - Lab. Director

B. quintana Ab, IgG <1:64  
--  
--

--INTERPRETIVE INFORMATION: Bartonella quintana Antibody, IgG  
-- Less than 1:64 ..... Negative: No significant level of  
-- Bartonella quintana IgG antibody  
-- detected.  
-- 1:64 - 1:128 ..... Equivocal: Questionable presence  
-- of Bartonella quintana IgG  
-- antibody detected. Repeat testing  
-- in 10-14 days may be helpful.  
-- 1:256 or greater ..... Positive: Presence of IgG  
-- antibody to Bartonella quintana  
-- detected, suggestive of current  
-- or past infection.  
--A low positive suggests past exposure or infection, while high  
--positive results may indicate recent or current infection, but is  
--inconclusive for diagnosis. Seroconversion between acute and

**ORSHER, STUART**  
D  
O  
C  
T  
O  
R  
C3070 - STUART ORSHER, ■■■  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) MO  
P: ■■■■■■■■■■

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: ■■■■■■■■■■

**Specimen ID: 104364919**  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
S  
A  
M  
P  
L  
E  
North America Eastern Time

**CLINICAL REPORT**

--convalescent sera is considered strong evidence of recent  
--infection. The best evidence for infection is a significant change  
--on two appropriately timed specimens where both tests are done in  
--the same laboratory at the same time.  
--Test developed and characteristics determined by ARUP  
--Laboratories. See Compliance Statement A: aruplab.com/CS

HEP. C Ab.	TNP	Non-Reactive
Test Not Performed: We were unable to perform the Hepatitis test(s) requested due to lipemia. Please resubmit a fasting specimen.		
HEP C Ab. (S/CO RATIO)	TNP	<0.89

(30)  
Performed by: ARUP  
500 Chipeta Way  
Salt Lake City, UT 84108

(58)  
Performed by: Viracor Eurofins Clinical Diagnostic  
1001 NW Technology Drive  
Lees Summit, MO 64086

Test Not Performed: One or more components were not available to perform calculation.

**H.PYLORI (IgG, IgA, IgM) REFERENCE RANGES**

RESULT (UNITS)	INTERPRETATION
<0.89	NEGATIVE
0.89-0.99	EQUIVOCAL
>0.99	POSITIVE

NOTE: This is a screening test for H.PYLORI. The diagnosis of gastritis and peptic ulcers should be assessed with the patients medical history and clinical symptoms. Results in the equivocal range should be rechecked with a new specimen in 2-5 weeks.

NOTE: The H. Pylori, IgM test was developed and its performance characteristics were determined by BioReference Laboratories. It has not been cleared by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform this test.

**ASSAY INFORMATION: Method ELISA**

NOTE: A result of equivocal or positive for B.burgdorferi (Lyme Ab) should not be interpreted without supplemental Western Blot testing.

**\*\*Lyme Antibody ranges (IgG/IgM)\*\***  
<0.91 = Negative  
0.91-1.09 = Equivocal

**ORSHER, STUART**  
D  
O  
C  
T  
O  
R  
M  
O  
NO  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070)  
P: [REDACTED]

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
P  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**Specimen ID: 104364919**  
S  
A  
M  
P  
L  
E  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

>1.09 = Positive  
Hepatitis B Result Interpretation  
(for reference use only)

Marker	LT/EA*	Acute	Past	Chronic	HBV
Vacc.					
HBsAg	+	+	-	+	-
HBeAg	+	+	-	+/-	-
HEP.B.CORE AB,IgM	-	+	-	-	-
HEP.B.CORE AB.	-	+	+	+	-
HBeAb	-	-	+/-	+/-	-
HBsAb	-	-	+/-	-	+

\*Late Incubation/Early Acute  
NOTE: In remote past infection, HBsAb level may be Negative or Non-Reactive in some patients.

ANA SCREEN	Positive *	Neg<1:80		
CRP	0.2	<0.5	mg/dL	
ESR (Sed-Rate)	15	<21	mm/hr	
FOLIC ACID	TNP	>5.38	ng/mL	

Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.

Folic Acid Range

	Units (ng/mL)
Normal	>5.38
Borderline deficient	3.38-5.38
Deficient	0.35-3.37
Excessive	>24.00

VITAMIN B12	TNP	211-911	pg/mL	
-------------	-----	---------	-------	--

Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.

25OH, VITAMIN D	TNP	32.0-100.0	ng/mL	
-----------------	-----	------------	-------	--

Test Not Performed: Unable to perform testing, specimen is LIPEMIC.

VITAMIN D,25-OH TEST INFORMATION

Range (ng/mL)	Suggested Interpretation
<20.0	Deficient
20.0-31.9	Insufficient
32.0-100.0	Sufficient
>100.0	Possible Adverse Effects

VIT D1,25DIHYDROXY	TNP	19.9-79.3	pg/mL	
--------------------	-----	-----------	-------	--

Test Not Performed: Unable to perform testing, specimen is LIPEMIC.

**ORSHER, STUART**  
D  
O  
C  
T  
O  
R  
P  
C3070 - STUART ORSHER, M.D.  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) MD  
P: [REDACTED]

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
P  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**Specimen ID: 104364919**  
S  
A  
M  
P  
L  
E  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

MUMPS VIRUS Ab.(IgG)	3.07	Immune=>1.09	
LEAD, BLOOD (CHILD)	<1.0	See Below	ug/dL

RANGES FOR LEAD, BLOOD  
Reference Range (ug/dL)  
Adult/Child <5.0  
Occupational <40.0

NOTE: Lead risk guidelines conform to CDC Guidelines. BioReference is an OSHA-APPROVED lab for lead testing.  
NOTE: Blood lead levels in the range 5.0-9.9 ug/dL have been associated with adverse health effects in children aged 6 years and younger.  
NOTE: All Lead results =>5.0 ug/dL are confirmed by repeat analysis.  
NOTE: Capillary and microtainer blood levels =>5.0 ug/dL may be due to contamination from lead found on the finger surface and requires confirmation on venous blood.  
NOTE: This test for LEAD was developed and its performance characteristics were determined by BioReference Laboratories. It has not been cleared by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform this test.

ASSAY INFORMATION: ICP-MS

Immunotyping,Serum	TNP	Negative	
--------------------	-----	----------	--

NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please RESUBMIT a fasting specimen at your earliest convenience.

MERCURY, BLOOD (30)	8	0-10	ug/L
---------------------	---	------	------

INTERPRETIVE INFORMATION: Mercury, Blood  
Blood mercury levels predominantly reflect recent exposure and are most useful in the diagnosis of acute poisoning as blood mercury concentrations rise sharply and fall quickly over several days after ingestion. Blood concentrations in unexposed individuals rarely exceed 20 ug/L. The provided reference interval relates to inorganic mercury concentrations. Dietary and non-occupational exposure to organic mercury forms may contribute to an elevated total mercury result. Clinical presentation after toxic exposure to organic mercury may include dysarthria, ataxia and constricted vision fields with mercury blood concentrations from 20 to 50 ug/L.  
Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS  
www.aruplab.com, Julio Delgado, MD - Lab. Director

RUBEOLA/MEASLES(IgG)	1.81	Immune=>1.09	
----------------------	------	--------------	--

**ORSHER, STUART**  
D  
D  
C  
T  
O  
R  
P:  
C3070 - STUART ORSHER, ■■■  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) MO  
P: ■■■■

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
P:  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: ■■■■

**Specimen ID: 104364919**  
S  
A  
M  
P  
L  
E  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
  
North America Eastern Time

**CLINICAL REPORT**

VARICELLA ZOSTER, IgM (3)	< 0.91	< 0.91	
---------------------------	--------	--------	--

REFERENCE RANGE for Varicella-zoster IgM Abs:  
Less than 0.91 .....Negative  
0.91 - 1.09 .....Equivocal  
Greater than 1.09 .....Positive

Results from any one IgM assay should not be used as a sole determinant of a current or recent infection. Because an IgM test can yield false positive results and low levels of IgM antibody may persist for more than 12 months post infection, reliance on a single test result could be misleading. Acute infection is best diagnosed by demonstrating the conversion of IgG from negative to positive. If an acute infection is suspected, consider obtaining a new specimen and submit for both IgG and IgM testing in two or more weeks.

VARICELLA ZOS. (IgG)	3.46	Immune=>1.09	
PTH(3), INTACT	TNP	13.8-85.0	pg/mL

Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.

RHEUMATOID (RF) TITER	<10	<14	IU/mL
RUBELLA, IgG	TNP	Immune=>9.9	IU/mL

Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.

**INTERPRETATION OF RESULTS FOR RUBELLA IgG ANTIBODY**

Results (IU/mL)	Interpretation
< 5.0	Negative Non-Immune
5.0 - 9.9	Equivocal Retest
> 9.9	Positive Immune

NOTE: Results interpreted as EQUIVOCAL indicate a level of antibody below the Positive (Immune) cut off. Repeat testing on a new specimen is suggested to assess antibody response after a booster shot or a viral syndrome.

ASSAY INFORMATION: Method Chemiluminescence (Siemens Diagnostics)

ANA TITER (IFA)	1:160 HI	<1:80	Titer
-----------------	----------	-------	-------

ANA PATTERN = HOMOGENEOUS AND SPECKLED

Antibodies To	Association	Frequency
ANA (Antinuclear Ab,	Screening test for SLE in symptomatic patients.	95-100%

**ORSHER, STUART**  
D  
O  
C  
T  
O  
R  
C3070 - STUART ORSHER, [REDACTED]  
9 EAST 79TH ST,  
NEW YORK, NY 10021  
Acct #: (C3070) MD  
P: [REDACTED]

**EPSTEIN, JEFFREY**  
P  
A  
T  
I  
E  
N  
T  
DOB: 01/20/1953 Age: 64 Y Sex: M  
U/FL: Bed:  
Rm:  
Patient ID:  
Address: 9 EAST 71ST STREET,  
NEW YORK, NY 10021  
P: [REDACTED]

**Specimen ID: 104364919**  
S  
A  
M  
P  
L  
E  
Date Of Report: 09/08/2017 11:30  
Date Collected: 08/30/2017 11:58  
Date Received: 08/30/2017 23:12  
North America Eastern Time

**CLINICAL REPORT**

indirect assay)

ANA Assist with diagnosis of Scleroderma (Systemic Sclerosis). 60-80%  
ANA Sjogren's Syndrome. 40-70%  
ANA Idiopathic Inflammatory Polymyositis or Dermatomyositis. 30-80%

Antibodies to specific (Extractable) Nuclear Antigens (ENA)/Proteins

dsDNA Characteristic of SLE. Rare in other CTDS. Highly associated with active disease. 25-85%  
Sm(Smith) Highly specific for SLE. Uncommon in other diseases. 15-30%  
SS A (Ro) Associated with SLE, Neonatal Lupus and Sjogren's Syndrome. 35-60%  
SS B (La) Associated with SLE. 15%  
SS B (La) Associated with Sjogren's Syndrome. 40-60%  
Scl-70 (anti DNA Topoisomerase) Associated with Diffuse Scleroderma and rarely co exists with anti-Centromere Abs which are associated with Limited Scleroderma Disease. 34-40%  
Jo-1 Associated with Polymyositis or Dermatomyositis. 20-25%  
Centromere Identified by staining pattern. Their presence is associated with CREST Syndrome (Limited Systemic Sclerosis). 80%  
U1 nRNP Used to categorize Mixed Connective Tissue Disease (MCTD). High Correlation  
Histone Proteins (Chromatin) Associated with drug induced LE. 90-100%

ref:Kavanaugh,A(et al.):Guidelines for Clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens. Arch.Pathol Lab Med. Vol.124,Jan 2000.

PNEUMO Ab TYPE 1 (58)		<0.3 LO	>1.3	ug/mL	
PNEUMO Ab TYPE 3 (58)	1.4		>1.3	ug/mL	
PNEUMO Ab TYPE 4 (58)		0.6 LO	>1.3	ug/mL	
PNEUMO Ab TYPE 8 (58)		0.4 LO	>1.3	ug/mL	
PNEUMO Ab TYPE 9 (9N) (58)		0.4 LO	>1.3	ug/mL	
PNEUMO Ab TYPE 12 (12F) (58)		<0.3 LO	>1.3	ug/mL	
PNEUMO Ab TYPE 14 (58)	23.2		>1.3	ug/mL	
PNEUMO Ab TYPE 19 (19F) (58)		0.8 LO	>1.3	ug/mL	
PNEUMO Ab TYPE 23 (23F) (58)		<0.3 LO	>1.3	ug/mL	
PNEUMO Ab TYPE 26 (6B) (58)		0.5 LO	>1.3	ug/mL	
PNEUMO Ab TYPE 5 (58)	7.8		>1.3	ug/mL	
PNEUMO Ab TYPE 51 (7F) (58)	1.5		>1.3	ug/mL	
PNEUMO Ab TYPE 56 (18C) (58)		1.3 LO	>1.3	ug/mL	
PNEUMO Ab TYPE 68 (9V) (58)		0.4 LO	>1.3	ug/mL	

Testing Performed At:  
Viracor Eurofins  
1001 NW Technology Drive  
Lee's Summit, MO 64086  
[REDACTED]  
CLIA# 26D-0983643

ARSENIC, BLOOD 2 2-23 ug/L

**ORSHER, STUART**  
 D  
 O  
 C  
 T  
 O  
 R  
 P:  
 C3070 - STUART ORSHER, [REDACTED]  
 9 EAST 79TH ST,  
 NEW YORK, NY 10021  
 Acct #: (C3070) MD  
 P: [REDACTED]

**EPSTEIN, JEFFREY**  
 P  
 A  
 T  
 I  
 E  
 N  
 T  
 P:  
 DOB: 01/20/1953 Age: 64 Y Sex: M  
 U/FL: Bed:  
 Rm:  
 Patient ID:  
 Address: 9 EAST 71ST STREET,  
 NEW YORK, NY 10021  
 P: [REDACTED]

**Specimen ID: 104364919**  
 S  
 A  
 M  
 P  
 L  
 E  
 Date Of Report: 09/08/2017 11:30  
 Date Collected: 08/30/2017 11:58  
 Date Received: 08/30/2017 23:12  
 North America Eastern Time

**CLINICAL REPORT**

A. Phagocytophila IgG Ab (24)	<1:64			
A. Phagocytophila IgM Ab (24)	<1:20			
B. Henselae IgG Ab (3)	1:64 *	< 1:64	titer	
B. Henselae IgM Ab (3)	<1:20	< 1:20	titer	

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Interpretation (24) SEE NOTE  
 ANTIBODY NOT DETECTED

REFERENCE RANGE IgG <1:64  
 IgM <1:20

Anaplasma phagocytophilum is the tick-borne agent causing Human Granulocytic Ehrlichiosis (HGE). HGE is distinct and separate from Human Monocytic Ehrlichiosis (HME), caused by Ehrlichia chaffeensis. Serologic crossreactivity between A. phagocytophilum and E. chaffeensis is minimal (5-15%).

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

- Quest Infectious Disease  
 33608 Ortega Hwy  
 (3)  
 Performed by: Quest Diagnostics Nichols Institute of Valencia  
 27027 Tournay Road  
 Valencia, CA 91355-5386
- (24)  
 Performed by: Quest Infectious Disease  
 33608 Ortega Highway  
 San Juan Capistrano, CA 92675  
 \*Medical Director Hollis J. Batterman, MD
- (30)  
 Performed by: ARUP  
 500 Chipeta Way  
 Salt Lake City, UT 84108
- (58)  
 Performed by: Viracor Eurofins Clinical Diagnostic

**ORSHER, STUART**  
 D  
 O C3070 - STUART ORSHER, M.D.  
 C  
 T 9 EAST 79TH ST,  
 O NEW YORK, NY 10021  
 R Acct #: (C3070) MO  
 P: [REDACTED]

**EPSTEIN, JEFFREY**  
 P DOB: 01/20/1953 Age: 64 Y Sex: M  
 A U/FL: Bed:  
 T Rm:  
 I Patient ID:  
 E Address: 9 EAST 71ST STREET,  
 N NEW YORK, NY 10021  
 T P: [REDACTED]

**S**  
**A**  
**M**  
**P**  
**L**  
**E**  
 Specimen ID: 104364919  
 Date Of Report: 09/08/2017 11:30  
 Date Collected: 08/30/2017 11:58  
 Date Received: 08/30/2017 23:12  
 North America Eastern Time

**CLINICAL REPORT**

1001 NW Technology Drive  
 Lees Summit, MO 64086

**INTERPRETATION OF RESULTS FOR RUBEOLA(MEASLES),MUMPS,VARICELLA VIRUS ABS.**

Range	Interpretation
< or = 0.90	Negative Non-Immune
0.91 - 1.09	Equivocal Retest
> or = 1.10	Positive Immune

Results interpreted as **EQUIVOCAL** indicate a level of antibody below the positive (Immune) cut off. Repeat testing on a new specimen is suggested to assess antibody response after a booster shot or a viral syndrome.

**NOTE:** The following tests: SERUM SELENIUM, SERUM CHROMIUM, ARSENIC BLOOD and CADMIUM BLOOD were developed and their performance characteristics were determined by BioReference Laboratories. They have not been cleared by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform these tests.

**NOTE:** The specimen submitted was **MARKEDLY** hemolyzed. Some results may be affected. Please resubmit as needed.

**NOTE:** Specimen submitted is **LIPEMIC**. This may cause inaccurate results. Please resubmit a fasting specimen at your earliest convenience.